Incretin mimetics, or GLP-1 receptor agonists, are a class of medications used to treat type 2 diabetes (off-label for type 1)
Additionally, GIPRs unique activation in the brain and white adipose tissue (WAT) might complement GLP-1R signaling, potentially improving therapeutic outcomes Figure 2
The lyophilized format helps maintain product integrity and allows easy reconstitution before administration
The American Diabetes Association Standards of Care acknowledge gastrointestinal tolerability as a key consideration when initiating GLP-1 receptor agonist therapy, recommending gradual dose titration to minimize these effects
Results We included 10 studies ( N = 300), one of which reported two independent samples
Available online at: (accessed December 31, 2021)